0 Evaluaciones

ID

12931

Descripción

Long-Term Therapy With Ribavirin for Chronic Hepatitis C; ODM derived from: https://clinicaltrials.gov/show/NCT00001854

Link

https://clinicaltrials.gov/show/NCT00001854

Palabras clave

  1. 6/1/16 6/1/16 -
Titular de derechos de autor

CC BY-NC 3.0

Subido en

6 de enero de 2016

DOI

Para solicitar uno, por favor iniciar sesión.

Licencia

Creative Commons BY-NC 3.0

Comentarios del modelo :

Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.

Comentarios de grupo de elementos para :

Comentarios del elemento para :


    Sin comentarios

    Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.

    Eligibility Chronic Hepatitis C NCT00001854

    Eligibility Chronic Hepatitis C NCT00001854

    Criteria
    Descripción

    Criteria

    age above 18 years, male or female.
    Descripción

    age above 18 years, male or female.

    Tipo de datos

    boolean

    Alias
    UMLS CUI [1]
    C0001779 (Age)
    SNOMED
    424144002
    LOINC
    LP28815-6
    UMLS CUI [2]
    C0079399 (Gender)
    SNOMED
    263495000
    LOINC
    LP61312-2
    elevated alanine (alt) or asparate (ast) aminotransferase activities averaging at least twice the upper limit of normal on three determinations taken at least one month apart during the previous 6 months. the mean of these three determinations will be defined as "baseline" alt and ast levels.
    Descripción

    elevated alanine (alt) or asparate (ast) aminotransferase activities

    Tipo de datos

    boolean

    Alias
    UMLS CUI [1]
    C0201836 (Alanine aminotransferase measurement)
    SNOMED
    34608000
    UMLS CUI [2]
    C0201899 (Aspartate aminotransferase measurement)
    SNOMED
    45896001
    presence of anti-hcv and hcv rna in serum tested at least once during the previous six months.
    Descripción

    anti-hcv and hcv rna

    Tipo de datos

    boolean

    Alias
    UMLS CUI [1]
    C0019196 (Hepatitis C)
    SNOMED
    50711007
    LOINC
    LA19423-5
    evidence of chronic hepatitis on liver biopsy done within the previous 12 months with a histology activity index of at least 6 (out of a maximum of 22).
    Descripción

    evidence of chronic hepatitis on liver biopsy done within the previous 12 months with a histology activity index of at least 6 (out of a maximum of 22).

    Tipo de datos

    boolean

    Alias
    UMLS CUI [1]
    C0019196 (Hepatitis C)
    SNOMED
    50711007
    LOINC
    LA19423-5
    contraindications to the use of alpha interferon, either in the form of specific contraindications to its use (depression, psychiatric illness, neurological impairment, severe thrombocytopenia, autoimmune disease), or the history of severe side effects or intolerance during a previous course of alpha interferon, or lack of a sustained virological (sustained lost of hcv rna from serum for more than six months after stopping treatment) response to an adequate course (6 months) of the combination of alpha interferon and ribavirin or (after september 1, 2003) the combination of peginterferon and ribavirin.
    Descripción

    Interferon

    Tipo de datos

    boolean

    Alias
    UMLS CUI [1]
    C1610033 (Interferon Alpha, Human)
    UMLS CUI [2]
    C0035525 (ribavirin)
    SNOMED
    35063004
    UMLS CUI [3]
    C0982327 (PEGINTERFERON)
    written informed consent.
    Descripción

    written informed consent.

    Tipo de datos

    boolean

    Alias
    UMLS CUI [1]
    C0021430 (Informed Consent)
    inclusion criteria for patients in 98-dk-0003:
    Descripción

    inclusion criteria for patients in 98-dk-0003:

    Tipo de datos

    boolean

    Alias
    UMLS CUI [1]
    C1512693 (Inclusion)
    an important group of patients who were enrolled in the current study, were patients who participated in the clinical research protocol 98-dk-0003 (combination of alpha interferon with long-term ribavirin for patients with chronic hepatitis c) and who did not have a sustained virological response to this treatment. these patients were eligible to enroll into the current study once they had finished the therapy and follow up period in that trial. these patients fit the inclusion criteria listed above with one exception: some patients were receiving ribavirin monotherapy as a part of their participation in 98-dk-0003. these patients were eligible to be immediately enrolled into this study without a medication-free period in between.
    Descripción

    clinical research protocol 98-dk-0003

    Tipo de datos

    boolean

    Exclusion Criteria
    Descripción

    Exclusion Criteria

    Alias
    UMLS CUI
    C0680251 (Exclusion Criteria)
    pregancy or, in women of childbearing potential, inability to practice adequate contraception. men with spouses or sexual partners of childbearing potential also be excluded if they are unable to practice adequate contraception.
    Descripción

    pregancy and contraception

    Tipo de datos

    boolean

    Alias
    UMLS CUI [1]
    C0032961 (Pregnancy)
    SNOMED
    289908002
    LOINC
    LP75920-6
    UMLS CUI [2]
    C0700589 (Contraceptive methods)
    SNOMED
    13197004
    significant systemic illnesses other than liver disease, including a history of congestive heart failure, cerebral vascular disease, renal failure (creatinine clearance less than 50 ml/min), and angina pectoris.
    Descripción

    significant systemic illnesses

    Tipo de datos

    boolean

    Alias
    UMLS CUI [1]
    C0009488 (Comorbidity)
    patients with an abnormal stress test or carotid untrasound will not be enrolled into this study.
    Descripción

    abnormal stress test or carotid untrasound

    Tipo de datos

    boolean

    Alias
    UMLS CUI [1]
    C1384495 (Cardiovascular stress testing)
    SNOMED
    76746007
    UMLS CUI [2]
    C0948945 (Carotid artery ultrasound)
    pre-existing anemia (hematocrit less than 32%) or known history of hemolytic anemia.
    Descripción

    anemia

    Tipo de datos

    boolean

    Alias
    UMLS CUI [1]
    C0002871 (Anemia)
    SNOMED
    271737000
    LOINC
    MTHU020823
    interferon or immunosuppressive therapy within the last 6 months.
    Descripción

    interferon or immunosuppressive therapy

    Tipo de datos

    boolean

    Alias
    UMLS CUI [1]
    C3652465 (Interferon)
    UMLS CUI [2]
    C0021081 (Immunosuppressive Agents)
    SNOMED
    69431002
    evidence of another form of liver disease in addition to viral hepatitis, such as autoimmune or alcoholic liver disease.
    Descripción

    liver disease

    Tipo de datos

    boolean

    Alias
    UMLS CUI [1]
    C0023895 (Liver diseases)
    SNOMED
    235856003
    LOINC
    LA17774-3
    active or recent (within one year) alcohol or drug abuse or psychiatric illness that is likely to interfere with compliance and requirements for safety monitoring during this study.
    Descripción

    active or recent (within one year) alcohol or drug abuse or psychiatric illness that is likely to interfere with compliance and requirements for safety monitoring during this study.

    Tipo de datos

    boolean

    Alias
    UMLS CUI [1,1]
    C1321605 (Compliance behavior)
    SNOMED
    405078008
    UMLS CUI [1,2]
    C0439801 (Limited (extensiveness))
    SNOMED
    255469002
    LOINC
    LP34047-8
    UMLS CUI [1,3]
    C0009488 (Comorbidity)

    Similar models

    Eligibility Chronic Hepatitis C NCT00001854

    Name
    Tipo
    Description | Question | Decode (Coded Value)
    Tipo de datos
    Alias
    Item Group
    age above 18 years, male or female.
    Item
    age above 18 years, male or female.
    boolean
    C0001779 (UMLS CUI [1])
    C0079399 (UMLS CUI [2])
    elevated alanine (alt) or asparate (ast) aminotransferase activities
    Item
    elevated alanine (alt) or asparate (ast) aminotransferase activities averaging at least twice the upper limit of normal on three determinations taken at least one month apart during the previous 6 months. the mean of these three determinations will be defined as "baseline" alt and ast levels.
    boolean
    C0201836 (UMLS CUI [1])
    C0201899 (UMLS CUI [2])
    anti-hcv and hcv rna
    Item
    presence of anti-hcv and hcv rna in serum tested at least once during the previous six months.
    boolean
    C0019196 (UMLS CUI [1])
    evidence of chronic hepatitis on liver biopsy done within the previous 12 months with a histology activity index of at least 6 (out of a maximum of 22).
    Item
    evidence of chronic hepatitis on liver biopsy done within the previous 12 months with a histology activity index of at least 6 (out of a maximum of 22).
    boolean
    C0019196 (UMLS CUI [1])
    Interferon
    Item
    contraindications to the use of alpha interferon, either in the form of specific contraindications to its use (depression, psychiatric illness, neurological impairment, severe thrombocytopenia, autoimmune disease), or the history of severe side effects or intolerance during a previous course of alpha interferon, or lack of a sustained virological (sustained lost of hcv rna from serum for more than six months after stopping treatment) response to an adequate course (6 months) of the combination of alpha interferon and ribavirin or (after september 1, 2003) the combination of peginterferon and ribavirin.
    boolean
    C1610033 (UMLS CUI [1])
    C0035525 (UMLS CUI [2])
    C0982327 (UMLS CUI [3])
    written informed consent.
    Item
    written informed consent.
    boolean
    C0021430 (UMLS CUI [1])
    inclusion criteria for patients in 98-dk-0003:
    Item
    inclusion criteria for patients in 98-dk-0003:
    boolean
    C1512693 (UMLS CUI [1])
    clinical research protocol 98-dk-0003
    Item
    an important group of patients who were enrolled in the current study, were patients who participated in the clinical research protocol 98-dk-0003 (combination of alpha interferon with long-term ribavirin for patients with chronic hepatitis c) and who did not have a sustained virological response to this treatment. these patients were eligible to enroll into the current study once they had finished the therapy and follow up period in that trial. these patients fit the inclusion criteria listed above with one exception: some patients were receiving ribavirin monotherapy as a part of their participation in 98-dk-0003. these patients were eligible to be immediately enrolled into this study without a medication-free period in between.
    boolean
    Item Group
    C0680251 (UMLS CUI)
    pregancy and contraception
    Item
    pregancy or, in women of childbearing potential, inability to practice adequate contraception. men with spouses or sexual partners of childbearing potential also be excluded if they are unable to practice adequate contraception.
    boolean
    C0032961 (UMLS CUI [1])
    C0700589 (UMLS CUI [2])
    significant systemic illnesses
    Item
    significant systemic illnesses other than liver disease, including a history of congestive heart failure, cerebral vascular disease, renal failure (creatinine clearance less than 50 ml/min), and angina pectoris.
    boolean
    C0009488 (UMLS CUI [1])
    abnormal stress test or carotid untrasound
    Item
    patients with an abnormal stress test or carotid untrasound will not be enrolled into this study.
    boolean
    C1384495 (UMLS CUI [1])
    C0948945 (UMLS CUI [2])
    anemia
    Item
    pre-existing anemia (hematocrit less than 32%) or known history of hemolytic anemia.
    boolean
    C0002871 (UMLS CUI [1])
    interferon or immunosuppressive therapy
    Item
    interferon or immunosuppressive therapy within the last 6 months.
    boolean
    C3652465 (UMLS CUI [1])
    C0021081 (UMLS CUI [2])
    liver disease
    Item
    evidence of another form of liver disease in addition to viral hepatitis, such as autoimmune or alcoholic liver disease.
    boolean
    C0023895 (UMLS CUI [1])
    active or recent (within one year) alcohol or drug abuse or psychiatric illness that is likely to interfere with compliance and requirements for safety monitoring during this study.
    Item
    active or recent (within one year) alcohol or drug abuse or psychiatric illness that is likely to interfere with compliance and requirements for safety monitoring during this study.
    boolean
    C1321605 (UMLS CUI [1,1])
    C0439801 (UMLS CUI [1,2])
    C0009488 (UMLS CUI [1,3])

    Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

    Watch Tutorial